There is a new method for molecular imaging detection of early gastric cancer

【Medical Fax】

Recently, the reporter of Science and Technology Daily learned from the Xinqiao Hospital of the Army Military Medical University that Professor Yang Shiming of the Department of Gastroenterology of the hospital, the team of researcher Wang Lei of the National Center for Nanoscience and the team of academician Xing Mengqiu of the University of Manitoba in Canada designed and constructed a bipyrene-peptide nanoprobe, which effectively solved the problem of
"difficult to distinguish" and "difficult to break" in early gastric cancer.
The relevant research results were recently published online in the materials science journal "Advanced Science"
.

Gastroscopy is currently the best way to diagnose gastric cancer early, but because the shape of the surface gland and blood vessels at the early gastric cancer lesion site is not obvious, endoscopists often "see but not recognize", so there is still a clinical missed diagnosis rate of 20%-40%, resulting in gastric cancer patients losing the best treatment time
.

In recent years, molecular imaging technology has developed rapidly in the field of biological imaging, which can show the early changes of cancer at the molecular and cellular levels, and has high sensitivity, which provides new ideas
for the diagnosis of early gastric cancer.

The newly studied bipyrene-peptide nanoprobe can target the neovascularization of early gastric cancer and anchor it to the lesion site for a long time by self-assembling into fibers in situ
.
At the same time, under the excitation of the blue laser endoscope in clinical application, the probe anchored at the lesion site can emit visible fluorescence, so as to achieve accurate diagnosis
of early gastric cancer.
Researchers have verified the targeting ability of the probe and its long-term imaging ability
to anchor tumor sites in in vitro experiments, mouse models of subcutaneous transplanted tumors, and surgical specimens of clinical resection.
In addition, researchers have also verified the ability of blue laser to stimulate imaging in vivo experiments in primary gastric cancer model rabbits, which indicates that the bipyrene-peptide nanoprobe has important clinical research significance
.